{
  "createdAt": "2025-10-25T01:56:36.515Z",
  "symbol": "HROW",
  "tradeDate": "2025-10-25",
  "entries": [
    {
      "id": 1,
      "persona": "Fundamentals Analyst",
      "name": "get_finnhub_balance_sheet",
      "input": {
        "ticker": "HROW",
        "freq": "quarterly",
        "limit": 20
      },
      "output": "### Balance Sheet (10-Q � 2025 � 2025-08-11)\n- Cash and cash equivalents: 52,963,000 usd\n- Accounts receivable, net: 78,822,000 usd\n- Inventories: 11,552,000 usd\n- Prepaid expenses and other current assets: 11,553,000 usd\n- Total current assets: 154,890,000 usd\n- Property, plant and equipment, net: 3,512,000 usd\n- Capitalized software costs, net: 1,478,000 usd\n- Operating lease right-of-use assets, net: 8,155,000 usd\n- Intangible assets, net: 176,666,000 usd\n- Goodwill: 332,000 usd\n- TOTAL ASSETS: 345,033,000 usd\n- Accounts payable and accrued expenses: 25,414,000 usd\n- Accrued rebates and copay assistance: 32,154,000 usd\n- Accrued payroll and related liabilities: 6,824,000 usd\n- Deferred revenue and customer deposits: 91,000 usd\n- Current portion of notes payable, net of unamortized debt discount: 183,619,000 usd\n- Current portion of operating lease obligations: 782,000 usd\n- Total current liabilities: 248,884,000 usd\n- Operating lease obligations, net of current portion: 8,366,000 usd\n- Notes payable, net of unamortized debt discount and current portion: 38,484,000 usd\n- � 8 additional rows truncated\n\n### Balance Sheet (10-Q � 2025 � 2025-05-08)\n- Cash and cash equivalents: 66,726,000 usd\n- Accounts receivable, net: 77,063,000 usd\n- Inventories: 10,716,000 usd\n- Prepaid expenses and other current assets: 15,030,000 usd\n- Total current assets: 169,535,000 usd\n- Property, plant and equipment, net: 3,568,000 usd\n- Capitalized software costs, net: 1,627,000 usd\n- Operating lease right-of-use assets, net: 8,337,000 usd\n- Intangible assets, net: 180,765,000 usd\n- Goodwill: 332,000 usd\n- TOTAL ASSETS: 364,164,000 usd\n- Accounts payable and accrued expenses: 39,159,000 usd\n- Accrued rebates and copay assistance: 31,153,000 usd\n- Accrued payroll and related liabilities: 7,605,000 usd\n- Deferred revenue and customer deposits: 145,000 usd\n- Current portion of notes payable, net of unamortized debt discount: 108,313,000 usd\n- Current portion of operating lease obligations: 611,000 usd\n- Total current liabilities: 186,986,000 usd\n- Operating lease obligations, net of current portion: 8,581,000 usd\n- Notes payable, net of unamortized debt discount and current portion: 112,501,000 usd\n- � 8 additional rows truncated\n\n### Balance Sheet (10-Q � 2024 � 2024-11-14)\n- Cash and cash equivalents: 72,601,000 usd\n- Accounts receivable, net: 53,734,000 usd\n- Inventories: 10,156,000 usd\n- Prepaid expenses and other current assets: 10,571,000 usd\n- Total current assets: 147,062,000 usd\n- Property, plant and equipment, net: 3,625,000 usd\n- Capitalized software costs, net: 1,869,000 usd\n- Operating lease right-of-use assets, net: 9,379,000 usd\n- Intangible assets, net: 189,272,000 usd\n- Goodwill: 332,000 usd\n- TOTAL ASSETS: 351,539,000 usd\n- Accounts payable and accrued expenses: 25,277,000 usd\n- Contingent consideration payable: 37,000,000 usd\n- Accrued rebates and copay assistance: 24,899,000 usd\n- Accrued payroll and related liabilities: 7,185,000 usd\n- Deferred revenue and customer deposits: 137,000 usd\n- Current portion of operating lease obligations: 507,000 usd\n- Total current liabilities: 95,005,000 usd\n- Operating lease obligations, net of current portion: 9,500,000 usd\n- Accrued expenses, net of current portion: 2,713,000 usd\n- � 10 additional rows truncated",
      "error": null,
      "startedAt": "2025-10-25T01:55:36.921Z",
      "finishedAt": "2025-10-25T01:55:38.182Z",
      "durationMs": null
    },
    {
      "id": 2,
      "persona": "Fundamentals Analyst",
      "name": "get_finnhub_cashflow",
      "input": {
        "ticker": "HROW",
        "freq": "quarterly",
        "limit": 20
      },
      "output": "### Cash Flow Statement (10-Q � 2025 � 2025-08-11)\n- Net income (loss): -12,785,000 usd\n- Depreciation and amortization of property, plant and equipment and software development costs: 961,000 usd\n- Amortization of intangible assets: 8,452,000 usd\n- Amortization of operating lease right-of-use assets: 399,000 usd\n- Provision for (recovery of) credit losses: 340,000 usd\n- Amortization of debt issuance costs and debt discount: 2,564,000 usd\n- Stock-based compensation: 5,431,000 usd\n- Accounts receivable: -37,211,000 usd\n- Inventories: 850,000 usd\n- Prepaid expenses and other current assets: -3,776,000 usd\n- Accounts payable, accrued expenses, accrued rebates and copay assistance: -24,009,000 usd\n- Accrued payroll and related liabilities: -2,672,000 usd\n- Deferred revenue and customer deposits: 47,000 usd\n- NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES: 18,865,000 usd\n- Investment in patent and trademark assets: 169,000 usd\n- Purchases of property, plant and equipment: 336,000 usd\n- NET CASH (USED IN) PROVIDED BY INVESTING ACTIVITIES: -505,000 usd\n- Payment of payroll taxes upon vesting of PSUs, RSUs and exercise of stock options: 12,769,000 usd\n- Proceeds from exercise of stock options: 125,000 usd\n- NET CASH USED IN FINANCING ACTIVITIES: -12,644,000 usd\n- � 4 additional rows truncated\n\n### Cash Flow Statement (10-Q � 2025 � 2025-05-08)\n- Net loss: -17,780,000 usd\n- Depreciation and amortization of property, plant and equipment and software development costs: 465,000 usd\n- Amortization of intangible assets: 4,226,000 usd\n- Amortization of operating lease right-of-use assets: 217,000 usd\n- Provision (recovery of) for credit losses: 114,000 usd\n- Amortization of debt issuance costs and debt discount: 1,275,000 usd\n- Stock-based compensation: 4,556,000 usd\n- Accounts receivable: -39,196,000 usd\n- Inventories: 14,000 usd\n- Prepaid expenses and other current assets: -299,000 usd\n- Accounts payable, accrued expenses, accrued rebates and copay assistance: -11,096,000 usd\n- Accrued payroll and related liabilities: -1,891,000 usd\n- Deferred revenue and customer deposits: 101,000 usd\n- NET CASH PROVIDED BY (USED IN) OPERATING ACTIVITIES: 19,668,000 usd\n- Investment in patent and trademark assets: 42,000 usd\n- Purchases of property, plant and equipment: 170,000 usd\n- NET CASH USED IN INVESTING ACTIVITIES: -212,000 usd\n- Proceeds from exercise of stock options: 23,000 usd\n- NET CASH PROVIDED BY (USED IN) FINANCING ACTIVITIES: 23,000 usd\n- NET CHANGE IN CASH AND CASH EQUIVALENTS: 19,479,000 usd\n- � 3 additional rows truncated\n\n### Cash Flow Statement (10-Q � 2024 � 2024-11-14)\n- Investment (loss) gain from Eton Pharmaceuticals: -3,171,000 usd\n- Net loss: -24,258,000 usd\n- Depreciation and amortization of property, plant and equipment and software development costs: 1,382,000 usd\n- Amortization of intangible assets: 7,708,000 usd\n- Amortization of operating lease right-of-use assets: 636,000 usd\n- (Recovery of) provision for credit losses: -20,000 usd\n- Amortization of debt issuance costs and debt discount: 2,985,000 usd\n- Stock-based compensation: 12,825,000 usd\n- Deferred income tax: 643,000 usd\n- Accounts receivable: 17,453,000 usd\n- Inventories: -711,000 usd\n- Prepaid expenses and other current assets: 983,000 usd\n- Accounts payable, accrued expenses, accrued rebates and copay assistance: 6,433,000 usd\n- Accrued payroll and related liabilities: 1,735,000 usd\n- Deferred revenue and customer deposits: 62,000 usd\n- NET CASH USED IN OPERATING ACTIVITIES: -4,423,000 usd\n- Net proceeds from sale of investment in Eton Pharmaceuticals: 5,510,000 usd\n- Investment in patent and trademark assets: 74,000 usd\n- Purchases of property, plant and equipment: 1,040,000 usd\n- NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES: 4,396,000 usd\n- � 9 additional rows truncated",
      "error": null,
      "startedAt": "2025-10-25T01:55:38.182Z",
      "finishedAt": "2025-10-25T01:55:38.757Z",
      "durationMs": null
    },
    {
      "id": 3,
      "persona": "Fundamentals Analyst",
      "name": "get_finnhub_income_stmt",
      "input": {
        "ticker": "HROW",
        "freq": "quarterly",
        "limit": 20
      },
      "output": "### Income Statement (10-Q � 2025 � 2025-08-11)\n- Total revenues: 111,573,000 usd\n- Cost of sales: 31,754,000 usd\n- Gross profit: 79,819,000 usd\n- Selling, general and administrative: 73,748,000 usd\n- Research and development: 5,894,000 usd\n- Total operating expenses: 79,642,000 usd\n- Income (loss) from operations: 177,000 usd\n- Interest expense, net: 12,956,000 usd\n- Other (expense) income, net: -6,000 usd\n- Total other expense, net: -12,962,000 usd\n- Income (loss) before income taxes: -12,785,000 usd\n- Net income (loss): -12,785,000 usd\n- Basic net income (loss) per share of common stock: -0 usdpshares\n- Diluted net income (loss) per share of common stock: 0 usdpshares\n- Weighted average number of shares of common stock outstanding, basic: 36,304,787 shares\n- Weighted average number of shares of common stock outstanding, diluted: 36,304,787 shares\n\n### Income Statement (10-Q � 2025 � 2025-05-08)\n- Total revenues: 47,831,000 usd\n- Cost of sales: 15,524,000 usd\n- Gross profit: 32,307,000 usd\n- Selling, general and administrative: 40,513,000 usd\n- Research and development: 3,026,000 usd\n- Total operating expenses: 43,539,000 usd\n- Loss from operations: -11,232,000 usd\n- Interest expense, net: 6,548,000 usd\n- Total other expense, net: -6,548,000 usd\n- Net loss: -17,780,000 usd\n- Basic net loss per share of common stock: -1 usdpshares\n- Diluted net loss per share of common stock: -1 usdpshares\n- Weighted average number of shares of common stock outstanding, basic: 35,826,452 shares\n- Weighted average number of shares of common stock outstanding, diluted: 35,826,452 shares\n\n### Income Statement (10-Q � 2024 � 2024-11-14)\n- Total revenues: 132,783,000 usd\n- Cost of sales: 35,110,000 usd\n- Gross profit: 97,673,000 usd\n- Selling, general and administrative: 94,275,000 usd\n- Research and development: 7,475,000 usd\n- Total operating expenses: 101,750,000 usd\n- Income (loss) from operations: -4,077,000 usd\n- Interest expense, net: 16,411,000 usd\n- Investment (loss) gain from Eton Pharmaceuticals: -3,171,000 usd\n- Other income (expenses), net: 76,000 usd\n- Total other expense, net: -19,506,000 usd\n- Loss before income taxes: -23,583,000 usd\n- Provision for income taxes: 675,000 usd\n- Net loss: -24,258,000 usd\n- Basic net loss per share of common stock: -1 usdpshares\n- Diluted net loss per share of common stock: -1 usdpshares\n- Weighted average number of shares of common stock outstanding, basic: 35,597,409 shares\n- Weighted average number of shares of common stock outstanding, diluted: 35,597,409 shares",
      "error": null,
      "startedAt": "2025-10-25T01:55:38.757Z",
      "finishedAt": "2025-10-25T01:55:39.411Z",
      "durationMs": null
    },
    {
      "id": 4,
      "persona": "Fundamentals Analyst",
      "name": "get_finnhub_company_insider_transactions",
      "input": {
        "ticker": "HROW",
        "lookback_days": 7,
        "limit": 10
      },
      "output": "No insider transactions recorded in the requested window.",
      "error": null,
      "startedAt": "2025-10-25T01:55:39.411Z",
      "finishedAt": "2025-10-25T01:55:39.782Z",
      "durationMs": null
    },
    {
      "id": 5,
      "persona": "Fundamentals Analyst",
      "name": "get_finnhub_company_insider_sentiment",
      "input": {
        "ticker": "HROW",
        "lookback_months": 6
      },
      "output": "No insider sentiment data retrieved for the requested window.",
      "error": null,
      "startedAt": "2025-10-25T01:55:39.782Z",
      "finishedAt": "2025-10-25T01:55:40.279Z",
      "durationMs": null
    },
    {
      "id": 6,
      "persona": "News Analyst",
      "name": "get_finnhub_news",
      "input": {
        "ticker": "HROW",
        "lookback_days": 7,
        "limit": 5
      },
      "output": "No Finnhub company news retrieved for HROW.",
      "error": null,
      "startedAt": "2025-10-25T01:56:12.534Z",
      "finishedAt": "2025-10-25T01:56:13.146Z",
      "durationMs": null
    },
    {
      "id": 7,
      "persona": "News Analyst",
      "name": "get_google_news",
      "input": {
        "query": "global macroeconomic news",
        "lookback_days": 7,
        "limit": 5
      },
      "output": "No Google News articles found for \"global macroeconomic news\".",
      "error": null,
      "startedAt": "2025-10-25T01:56:13.146Z",
      "finishedAt": "2025-10-25T01:56:13.648Z",
      "durationMs": null
    },
    {
      "id": 8,
      "persona": "News Analyst",
      "name": "get_reddit_news",
      "input": {
        "ticker": "HROW",
        "limit": 5
      },
      "output": "Reddit sentiment for HROW (query: HROW stock)\n- Total posts (7d): 1\n- Total upvotes: 3\n- Average comments per post: 3\n\nTop subreddits:\n• r/KPTI: 1 mentions\n\nTrending posts:\n• Opaleye Management Inc. Acquires Significant Stake in Karyopharm Therapeutics Inc — Score 3 | Comments 3\n  https://www.reddit.com/r/KPTI/comments/1of1aim/opaleye_management_inc_acquires_significant_stake/\n",
      "error": null,
      "startedAt": "2025-10-25T01:56:13.648Z",
      "finishedAt": "2025-10-25T01:56:14.826Z",
      "durationMs": null
    },
    {
      "id": 9,
      "persona": "Social Analyst",
      "name": "get_reddit_news",
      "input": {
        "ticker": "HROW",
        "limit": 10
      },
      "output": "Reddit sentiment for HROW (query: HROW stock)\n- Total posts (7d): 1\n- Total upvotes: 3\n- Average comments per post: 3\n\nTop subreddits:\n• r/KPTI: 1 mentions\n\nTrending posts:\n• Opaleye Management Inc. Acquires Significant Stake in Karyopharm Therapeutics Inc — Score 3 | Comments 3\n  https://www.reddit.com/r/KPTI/comments/1of1aim/opaleye_management_inc_acquires_significant_stake/\n",
      "error": null,
      "startedAt": "2025-10-25T01:56:26.977Z",
      "finishedAt": "2025-10-25T01:56:27.600Z",
      "durationMs": null
    }
  ],
  "summary": {
    "totalCalls": 9
  }
}